APA

Lachmann N., Czarnecki K., Brennig S., Phaltane R., Heise M., Heinz N., Kempf H., Dilloo D., Kaever V., Schambach A., Heuser M. & Moritz T. (20160224). Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy. : Leukemia.

Chicago

Lachmann N, Czarnecki K, Brennig S, Phaltane R, Heise M, Heinz N, Kempf H, Dilloo D, Kaever V, Schambach A, Heuser M and Moritz T. 20160224. Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy. : Leukemia.

Harvard

Lachmann N., Czarnecki K., Brennig S., Phaltane R., Heise M., Heinz N., Kempf H., Dilloo D., Kaever V., Schambach A., Heuser M. and Moritz T. (20160224). Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy. : Leukemia.

MLA

Lachmann N, Czarnecki K, Brennig S, Phaltane R, Heise M, Heinz N, Kempf H, Dilloo D, Kaever V, Schambach A, Heuser M and Moritz T. Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy. : Leukemia. 20160224.